Our analysis shows homozygous PTEN deletions are consistently more strongly associated with high-grade tumours and severe clinical outcomes compared to hemizygous deletions, aligning with previous findings linking complete PTEN inactivation to metastatic and treatment-resistant prostate cancers [28,38,39]. This evidence concerns the gene PTEN and prostate cancer.